AstraZeneca has entered into US $ 1.35 billion agreement with Bristol-Myer Squibb to get access of Bristol’s two diabetes compounds --- Saxagliptin and Dapagliflozin currently in Phase III and Phase IIb development respectively. Under the terms of the alliance, the majority of development costs will be funded by AstraZeneca from 2007 through 2009. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor disclosed in the U.S. Patent No. 6,395,767 (the ‘767 patent) whereas Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor. Earlier, Bristol also entered into agreement with Otsuka Pharmaceutical Co. to develop and commercialize Saxagliptin in Japan. Read more. Read more.